| General Information of Drug Metabolite (DM) (ID: DM006708) |
| DM Name |
ABT-751 glucuronide
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
UDP-glucuronosyltransferase 1A1 (UGT1A1)
|
DME0004
|
| Unclear - Unclear |
ABT-751
|
[1] |
|
UDP-glucuronosyltransferase 1A4 (UGT1A4)
|
DME0048
|
| Unclear - Unclear |
ABT-751
|
[1] |
|
UDP-glucuronosyltransferase 1A8 (UGT1A8)
|
DME0064
|
| Unclear - Unclear |
ABT-751
|
[1] |
|
UDP-glucuronosyltransferase 2B7 (UGT2B7)
|
DME0040
|
| Unclear - Unclear |
ABT-751
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| ABT-751 |
DR1853
|
Phase 2 |
Breast cancer |
|
|
| References |
| 1 |
Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751. Pharmacogenet Genomics. 2013 Jul;23(7):374-81.
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
